Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Benign Hematology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.


Journal Scan / Research · October 24, 2022

Outcomes After Cobimetinib Treatment in Rosai–Dorfman Disease Based on MAPK Pathway Alteration Status

JAMA Oncology


Additional Info

JAMA Oncology
Outcomes After Treatment With Cobimetinib in Patients With Rosai-Dorfman Disease Based on KRAS and MEK Alteration Status
JAMA Oncol 2022 Oct 06;[EPub Ahead of Print], JP Abeykoon, KL Rech, JR Young, A Ravindran, GJ Ruan, S Dasari, DM Morlote, RL King, C Rummage, S Zanwar, AM Acosta-Medina, WO Tobin, MV Shah, NN Bennani, R Vassallo, JH Ryu, MJ Koster, CJ Davidge-Pitts, TE Witzig, G Goyal, RS Go

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading